Journal
EINSTEIN-SAO PAULO
Volume 20, Issue -, Pages -Publisher
INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
DOI: 10.31744/einstein_journal/2022AO6985
Keywords
Biomarkers; Chromogranin A; Neuroendocrine tumors; Gastro-enteropancreatic neuroendocrine tumor; Blood platelets; Neutrophils; Lutetium; Intention to treat analysis
Categories
Funding
- Research Support Center (NAP) at Hospital Israelita Albert Einstein
Ask authors/readers for more resources
This study aimed to investigate the association of red cell blood counts and liver panel tests with outcomes in patients with gastroenteropancreatic neuroendocrine tumors who underwent systemic antineoplastic treatments. Laboratory tests were conducted, and the results showed that chromogranin A, neutrophils, and platelets-to-lymphocyte ratio were associated with disease progression.
Objective: To determine the association of red cell blood counts, and liver panel tests to predict outcomes in patients with gastroenteropancreatic neuroendocrine tumors who underwent systemic antineoplastic treatments. Methods: Patients with gastroenteropancreatic neuroendocrine tumors in systemic treatment were assessed according to laboratory tests within the same period. Progression free survival was determined by the period between the beginning of treatment and the date of progression. We used conditional models (PWP model) to verify the association between laboratory tests and tumor progression. The level of significance used was 5%. Results: A total of 30 treatments given to 17 patients in the intention-to-treat population were evaluated. Treatment included octreotide, lanreotide, everolimus, lutetium, and chemotherapy. We had statistically significant results in chromogranin A, neutrophils and platelets-to-lymphocyte ratio. The risk of progression increases by 2% with the addition of 100ng/mL of chromogranin A (p=0.034), 4% with the increase of 100 neutrophil units (p=0.006), and 21% with the addition of 10 units in platelets-to-lymphocyte ratio (p=0.002). Conclusion: Chromogranin A, neutrophils and platelets-to-lymphocyte ratio were associated with disease progression during systemic treatment in gastroenteropancreatic neuroendocrine tumors. Further prospective studies with larger cohorts are necessary to validate our findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available